Lacosamid 1a Pharma (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilising hyper‑excitable neurons, it reduces the ability of abnormal electrical impulses to propagate, thereby decreasing seizure frequency.

The dosage of Lacosamid 1a Pharma is determined individually by a qualified prescriber based on the patient’s age, weight, renal and hepatic function, and response to therapy. The prescribing physician will set the appropriate starting dose and titration schedule.

Safety data for lacosamide in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation rather than fast inactivation, which may result in a different side‑effect profile and lower risk of certain drug‑drug interactions. Clinical choice depends on individual patient characteristics and therapeutic goals.

Store the product at ambient temperature, preferably below 25 °C, in the original packaging. Protect it from moisture and direct sunlight to maintain stability throughout its shelf life.

Lacosamid 1a Pharma is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or split unless advised.

Serious adverse reactions, although rare, can include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions, suicidal ideation, and hypersensitivity reactions. Patients should be monitored for these events and seek immediate medical attention if they occur.

Individuals with known hypersensitivity to lacosamide or any excipients, patients with significant cardiac conduction disorders, and those taking contraindicated medications that may cause dangerous PR‑interval prolongation should avoid this product unless a specialist determines it is safe.